Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history study
Erin DeSpain, Nicholas E. Johnson, Valeria Sansone, Bakri Elsheikh et al.
Journal
PLoS ONE
Topics
Genetic Neurodegenerative Diseases
article
Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history study
Erin DeSpain, Nicholas E. Johnson, Valeria Sansone, Bakri Elsheikh, Jacinda B. Sampson, Richard H Roxburgh, Charles A. Thornton, Benedikt G. H. Schoser, Karlien Mul, Jeanne Dekdebrun, Catherine Laverty, Ericka Greene, Cynthia Gagnon, Jeffrey Statland, Man Hung, Jennifer K. Raymond, Johanna Hamel, Thomas Ragole, Christopher T. Turner, Kate Eichinger, Andrea Swenson, Perry B. Shieh, Matthew Wicklund, S. H. Subramony, Emma Matthews, Masanori Takahashi
article en
Abstract
No abstract available for this paper.
Publication Tag
PLoS ONEVol. 20(12)
Institutions
University of Iowa (US), Houston Methodist (US), Radboud University Nijmegen (NL), University of Auckland (NZ), University of California, Los Angeles (US), The University of Texas at San Antonio Health Science Center (US), Virginia Commonwealth University (US), St George’s University Hospitals NHS Foundation Trust (GB), The Ohio State University Wexner Medical Center (US), Radboud University Medical Center (NL), University of Rochester Medical Center (US), University of Florida (US), University of California San Diego (US), Urology San Antonio (US), Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean (CA), Centro Clinico Nemo (IT), University of Kansas Medical Center (US), Friedrich Baur Stiftung (DE), National Hospital for Neurology and Neurosurgery (GB), University College London (GB), University of Colorado Anschutz Medical Campus (US), Ludwig-Maximilians-Universität München (DE), Florida College (US), Stanford University (US), The University of Osaka (JP)